Claims

1. A pharmaceutical composition comprising:
   (a) nebivolol and/or a pharmaceutically acceptable salt thereof, and
   (b) a liquid vehicle comprising a semifluorinated alkane

   wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle comprising a semifluorinated alkane.

2. The pharmaceutical composition according to claim 1, comprising a semifluorinated alkane of the formula (II)

   $$CF_3(CF_2)_n(CH_2)_mCH_3 \quad (II),$$

   wherein n is an integer from 2 to 10 and m is an integer from 2 to 10;

   or

   wherein n is an integer from 3 to 5 and m is an integer from 4 to 7

3. The pharmaceutical composition of claim 1 or claim 2, wherein the semifluorinated alkane is selected from the group consisting of 1-perfluorobutyl-pentane ($CF_3(CF_2)_3(CH_2)_4CH_3$; F4H5) and 1-perfluorohexyl-octane ($CF_3(CF_2)_5(CH_2)_7CH_3$, F6H8).

4. The pharmaceutical composition of any one of the preceding claims, wherein the composition is free of water and/or a preservative.

5. The pharmaceutical composition of any one of the preceding claims, wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle at a concentration of from 0.3 to 1.5 % (w/v).

6. The pharmaceutical composition of any one of the preceding claims, wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle at a concentration of from 0.45 to 1.0 % (w/v).

7. The pharmaceutical composition of any one of the preceding claims, comprising the nebivolol in the form of nebivolol hydrochloride.

8. The pharmaceutical composition of any one of the preceding claims, essentially consisting of nebivolol hydrochloride and 1-perfluorohexyl-octane (F6H8).

9. The pharmaceutical composition of any one of claims 4 to 8, wherein at least about 90% of the suspended particles of the nebivolol and/or a pharmaceutically acceptable salt thereof have a size of not more than about 15 µm.

10. The pharmaceutical composition of any one of the preceding claims for use as a medicament.

11. The pharmaceutical composition for use according to claim 10, in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

12. The pharmaceutical composition for use according to claim 11, wherein the composition is administered to the eye of a subject, preferably up to two times daily.

13. The pharmaceutical composition for the use according to claim 11 or claim 12, wherein the pharmaceutical composition is administered in a dose volume per eye of 8 to 15 µl, preferably from about 10 to 12 µl.

14. The pharmaceutical composition for the use according to any one of claims 11 to 13, wherein the pharmaceutical composition is administered in a single dose per eye of about 45 to about 120 µg.

15. A kit comprising the pharmaceutical composition according to any one of the preceding claims and a container for holding the pharmaceutical composition.